Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
- PMID: 28898689
- DOI: 10.1016/j.ccell.2017.08.011
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Abstract
In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment on
-
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003. Cancer Cell. 2017. PMID: 28898695 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
